161,95 €
161,95 €
inkl. MwSt.
Sofort per Download lieferbar
payback
81 °P sammeln
161,95 €
161,95 €
inkl. MwSt.
Sofort per Download lieferbar

Alle Infos zum eBook verschenken
payback
81 °P sammeln
Als Download kaufen
161,95 €
inkl. MwSt.
Sofort per Download lieferbar
payback
81 °P sammeln
Jetzt verschenken
161,95 €
inkl. MwSt.
Sofort per Download lieferbar

Alle Infos zum eBook verschenken
payback
81 °P sammeln
  • Format: PDF

Pharmaceutical Perspectives of Cancer Therapeutics presents a comprehensive yet easy-to-follow review of the principles, current progress and state-of-the-art of cancer therapeutics. The complexity of cancer demands an integrated understanding from both cancer biology and pharmaceutical dosage forms and drug delivery in order to warrant a successful therapeutic regimen. This book combines and merges the knowledge from these two aspects. Internationally acclaimed experts with a multi-disciplinary background, including scientists and clinicians from both academia and industries have contributed…mehr

  • Geräte: PC
  • ohne Kopierschutz
  • eBook Hilfe
  • Größe: 11.39MB
Produktbeschreibung
Pharmaceutical Perspectives of Cancer Therapeutics presents a comprehensive yet easy-to-follow review of the principles, current progress and state-of-the-art of cancer therapeutics. The complexity of cancer demands an integrated understanding from both cancer biology and pharmaceutical dosage forms and drug delivery in order to warrant a successful therapeutic regimen. This book combines and merges the knowledge from these two aspects. Internationally acclaimed experts with a multi-disciplinary background, including scientists and clinicians from both academia and industries have contributed to this book to bridge the following areas between basic research and clinical application, pharmaceutical drug development processes and regulatory issues, drug design and delivery, laboratory and translational experimentation, marketing and postmarketing surveillance.

Main features of the book:

  • Anticancer drug development and regulatory processes.
  • Strategies to suppress tumor angiogenesis and metastasis, overcome multi-drug resistance in cancer, target telomerase and apoptosis pathways.
  • Therapeutic approaches to employ monoclonal antibody and cancer vaccines.
  • Introduction of new concepts such as cancer stem cells and new technologies such as nanobiotechnology, RNA interference, microRNA, and cancer cell gene profiling.
  • Use of lipids, polymers and peptides for drug delivery and targeting to cancer cells or specific organs.
  • Utilization of bioimaging and HIF-1 knockout animal models in cancer study.
  • Clinical trials designs and principles

Dieser Download kann aus rechtlichen Gründen nur mit Rechnungsadresse in A, B, BG, CY, CZ, D, DK, EW, E, FIN, F, GR, HR, H, IRL, I, LT, L, LR, M, NL, PL, P, R, S, SLO, SK ausgeliefert werden.

Autorenporträt
Yi Lu graduated with B.S. in Biochemistry from Fudan University in Shanghai, China in 1984, and Ph.D. in Biochemistry and Molecular Biology from University of Nebraska Medical Center, Omaha, NE, USA in 1992. He is currently an Associate Professor at the Departments of Pathology, Medicine, and Pharmaceutical Sciences, University of Tennessee Health Science Center, Memphis, TN, USA. His research interests include tumor angiogenesis and metastasis, gene therapy for prostate cancer and breast cancer, targeted gene expression, and exploration of novel apoptosis-inducing genes. He has more than 50 publications and holds five patents. Ram I Mahato is a full time Associate Professor in the Department of Pharmaceutical Sciences at the University of Health Science Center Memphis. He was a Research Assistant Professor at the University of Utah Salt Lake City, Senior Scientist at GeneMedicine, Inc., The Woodland, TX, and postdoctoral fellow at the University of Southern California in Los Angeles, Washington University in St Louis and Kyoto University, Japan. He received his B.S. in Pharmaceutics from China Pharmaceutical University in 1989 and PhD in Pharmaceutics and Drug Delivery from the University of Strathclyde in 1992. He is an author or co-author of 79 peer reviewed articles and book chapters. He has also edited/written three books and is a special features editor of Pharmaceutical Research and on the editorial board of the Journal of Drug Targeting, Expert Opinion on Drug Delivery, and Transplantation and Risk Management. His research includes delivery and targeting of small molecules, oligonucleotides, siRNA and genes.